RPG Life Sciences Ltd
Incorporated in 2007, RPG Life Sciences Ltd manufactures and markets Formulations (Finished Dosage Forms) and Active Pharma Ingredients[1]
- Market Cap ₹ 3,268 Cr.
- Current Price ₹ 1,979
- High / Low ₹ 2,725 / 1,772
- Stock P/E 29.2
- Book Value ₹
- Dividend Yield 1.01 %
- ROCE %
- ROE %
- Face Value ₹ 8.00
Pros
Cons
- Earnings include an other income of Rs.95.3 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| 653 | |
| 494 | |
| Operating Profit | 160 |
| OPM % | 24% |
| 95 | |
| Interest | 1 |
| Depreciation | 21 |
| Profit before tax | 233 |
| Tax % | 21% |
| 183 | |
| EPS in Rs | 110.79 |
| Dividend Payout % | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 36% |
| 3 Years: | 35% |
| 1 Year: | -20% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| Equity Capital | |
| Reserves | |
| Total Liabilities | |
| CWIP | |
| Investments | |
| Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| Net Cash Flow |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| Debtor Days | |
| Inventory Days | |
| Days Payable | |
| Cash Conversion Cycle | |
| Working Capital Days | |
| ROCE % |
Documents
Announcements
-
General Updates
30 Jan - Agreement with First Energy for wind-solar captive power; up to Rs1.50 crore equity subscription for Ankleshwar plant.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 28 Jan
- Announcement under Regulation 30 (LODR)-Investor Presentation 28 Jan
-
Announcement under Regulation 30 (LODR)-Investor Presentation
27 Jan - Investor Presentation in respect to the Board Meeting held on January 27, 2026
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
27 Jan - Q3 FY26 revenue Rs180.0cr (+4.2% Y-o-Y); EBITDA margin 24.0%; 9M revenue Rs530.6cr.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
Concalls
-
Jan 2026TranscriptAI SummaryPPT
-
Oct 2025Transcript PPT REC
-
Jul 2025TranscriptAI SummaryPPT
-
Jun 2025TranscriptAI SummaryPPT
-
Apr 2025Transcript PPT REC
-
Nov 2024TranscriptAI SummaryPPT
-
Sep 2024TranscriptPPTREC
-
Jul 2024TranscriptAI SummaryPPT
-
Jun 2024TranscriptAI SummaryPPT
-
May 2024Transcript PPT
-
Feb 2024TranscriptAI SummaryPPT
-
Oct 2023Transcript PPT
-
Jul 2023TranscriptAI SummaryPPT
-
Jun 2023TranscriptAI SummaryPPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
-
Oct 2022Transcript PPT
-
Sep 2022TranscriptAI SummaryPPT
-
Aug 2022TranscriptAI SummaryPPT
-
May 2022Transcript PPT
-
Feb 2022TranscriptAI SummaryPPT
-
Jan 2022TranscriptAI SummaryPPT
-
Nov 2021Transcript PPT
-
Aug 2021TranscriptAI SummaryPPT
-
Jun 2021TranscriptAI SummaryPPT
-
Jun 2019TranscriptAI SummaryPPT
-
Jun 2018TranscriptAI SummaryPPT
-
Nov 2017TranscriptAI SummaryPPT
-
Jun 2017TranscriptAI SummaryPPT
-
Nov 2016TranscriptAI SummaryPPT
-
Jun 2016TranscriptAI SummaryPPT
Business Overview:[1]
RPGLS is a part of the RPG Group. It started as a joint venture with G.D Searle and was renamed when G.D Searle withdrew its India operations. Currently, the group has major listed companies like KEC International, CEAT, Zensar Tech, etc.
RPGLS is an integrated research based pharmaceutical company operating in domestic and international markets in branded formulations, global generics and APIs